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EDITORIAL COMMENT

Coronary Vasospasm
Not Gone But Often Forgotten*
Michael P. Savage, MD,a Tabitha G. Moe, MDb

I

t has been more than 60 years since the initial

with relatively normal coronary angiograms, provoc-

description of vasospastic angina by Prinzmetal

ative testing with acetylcholine or ergot derivatives is

et al. (1). This seminal report was a series of 32

infrequently performed in contemporary practice. In

patients with a clinical syndrome characterized by

addition to recurrent symptomatic episodes, CAS may

angina occurring at rest associated with transient

cause myocardial infarction or sudden cardiac death,

ST-segment elevation and prompt relief with nitro-

and therefore, failure of diagnosis can have poten-

glycerin. Classiﬁed as a “variant form of angina” to

tially dire consequences.

distinguish it from the classic exertional angina of

Another variation on the theme of unrecognized

Heberden, the researchers astutely postulated that

CAS is seen in patients with chest pain syndromes

the cause of these attacks was a “temporary increased

and signiﬁcant angiographic stenosis. Vishnevsky

tonus” in large coronary arteries.

et al. (5) described a series of patients referred for

Although the prevalence of coronary artery spasm

percutaneous coronary intervention (PCI) with >70%

(CAS) is unknown, evidence suggests that it remains

stenosis on angiography that resolved after adminis-

underdiagnosed and undertreated. A large registry

tration of intracoronary nitroglycerin. PCI was de-

study showed that 62% of patients undergoing elec-

ferred, and patients were successfully treated with

tive cardiac catheterization for suspected coronary

medication. The importance of considering CAS dur-

artery disease had no obstructive disease (2). A pro-

ing diagnostic cardiac catheterization was further

spective study of 124 patients with typical angina but

illustrated by Mohammed et al. (6), who found that in

angiographically normal coronary arteries evaluated

patients with prior coronary artery bypass grafting

the frequency of provocable CAS using intracoronary

(CABG) for left main stenosis, 4.1% had no evidence of

acetylcholine (3). Epicardial CAS was demonstrated in

left main disease on follow-up coronary angiography,

28% of patients. An additional 34% of patients had

suggesting that vasospasm was responsible for the

evidence of microvascular spasm. Similarly, in the

original lesion (6). Other investigators have reported

CorMICA

trial,

even higher rates of unrecognized left main vaso-

acetylcholine testing induced epicardial vasospasm in

spasm in patients referred for CABG (7). These studies

37% of patients with angina but no obstructive coro-

underscore the importance of intracoronary nitro-

nary artery disease (4). Despite the accruing evidence

glycerin during diagnostic coronary angiography and

for CAS as a frequent cause of chest pain in patients

before PCI to avert unnecessary revascularization

(Coronary

Microvascular

Angina)

procedures (8). It is notable that current PCI guidelines neglect to mention the use of intracoronary
nitroglycerin, which has been dubbed the “forgotten
*Editorials published in JACC: Case Reports reﬂect the views of the authors and do not necessarily represent the views of JACC: Case Reports or

stepchild of cardiovascular guidelines” (5).
This issue of JACC: Case Reports presents 2 case

the American College of Cardiology.

studies of patients with coronary vasospasm offering

From the aThomas Jefferson University, Philadelphia, Pennsylvania, USA;

different, important perspectives. The report by Arps

and the bUniversity of Arizona College of Medicine, Phoenix, Arizona,

et al. (9) reinforces past lessons on the importance of

USA.

clinical vigilance for the role of vasospasm in chest

The authors attest they are in compliance with human studies commit-

pain syndromes, and the report by Pereyra et al. (10)

tees and animal welfare regulations of the authors’ institutions and Food
and Drug Administration guidelines, including patient consent where

points the way toward future novel approaches for

appropriate. For more information, visit the Author Center.

the treatment of CAS.
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Arps et a. (9) describe a 69-year-old man under-

nondihydropyridine) in combination. There is a

going cardiac catheterization for unstable angina 7

paucity of data on the efﬁcacy of this approach, and

years after CABG. Initial injection of the vein graft to a

new alternative options are needed to address the

diagonal branch demonstrated a high-grade proximal

difﬁcult problem of vasospastic angina refractory to

stenosis and was complicated by ventricular ﬁbrilla-

conventional therapies.

tion. After resuscitation, PCI was initiated, but repeat

The case report by Pereyra et al. (10) describes the

angiography following coronary guidewire placement

novel use of riociguat to successfully treat a 77-year-

revealed complete return of vein graft patency, indi-

old woman with refractory vasospastic angina. Rio-

cating that the original stenosis was due to vaso-

ciguat is an oral drug, a soluble guanylate cyclase

spasm. A common perception is that spasm of

stimulator approved for the treatment of pulmonary

aortocoronary venous bypass grafts is relatively rare

arterial hypertension (PAH) in World Health Organi-

outside of the early post-operative period. However,

zation (WHO) group 1 patients. It is the only agent

cases of vein graft spasm have long been recognized

approved by the U.S. Food and Drug Administration

(11,12). Kafka et al. (13) reported vein graft spasm in 24

for WHO group 4 patients with chronic thromboem-

of 1,264 (1.9%) patients undergoing routine post-

bolic pulmonary hypertension. The drug has been

CABG surveillance angiography. The location of

shown to improve exercise capacity and WHO func-

spasm was typically in the proximal grafts, which

tional class and to delay clinical worsening in patients

were often technically difﬁcult to engage, suggesting

with PAH (17,18).

that catheter-induced spasm was the proximate cause
in many of the cases.

In this case study, riociguat was used off label to
treat longstanding vasospastic angina that was re-

This case report has valuable take-home lessons.

fractory to multiple conventional drugs. Riociguat

The possibility of CAS needs to be considered even in

promotes vasodilation via cyclic guanosine mono-

cases where it may be least expected. Vein graft spasm,

phosphate, which is produced in lung parenchyma by

although uncommon, does occur, and failure to make

guanylate cyclase in response to nitric oxide. Rioci-

the diagnosis could lead to unnecessary stenting (8).

guat increases the activity of soluble guanylate

The present report is a case in point—vasospasm was

cyclase by 2 mechanisms: it sensitizes soluble gua-

not initially considered, as PCI had commenced, until

nylate cyclase to endogenous nitric oxide and also

repeat angiography showed spontaneous resolution of

directly stimulates guanylate cyclase receptors inde-

the stenosis. A more advisable action during this pro-

pendent of nitric oxide (18). That the vasodilatory

cedure would have been to administer intracoronary

effects occur systemically and not only in the pul-

nitroglycerin ﬁrst before proceeding with PCI precisely

monary circulation allows its potential as a thera-

for this reason (5). Fortunately, CAS was recognized,

peutic agent in the treatment of coronary vasospasm.

and the patient was treated successfully with medi-

Other agents affecting this nitric oxide pathway may

cation. PCI and stents are generally not recommended

also be potential therapeutic targets. In the United

for the treatment of CAS in the absence of severe

States, riociguat remains on patent and is not a

atherosclerotic disease. In patients with CAS, PCI does

preferred

not eliminate the need for continued antispasm

resulting in what is often a cost-prohibitive therapy

medication because spasm has the propensity to

for patients with PAH.

reoccur outside of the stented segment (14).
Management

vasospastic

many

insurance

providers,

Larger controlled studies are necessary before riociguat can be recommended for the treatment of CAS.

avoidance of precipitating factors, especially ciga-

The drug has notable side effects and drug in-

rette smoking and drugs that potentiate coronary

teractions. Secondary to the systemic effects of vaso-

vasoconstriction, such as cocaine, sympathomimetic

dilation, hypotension, headaches, and vasomotor

agents,

beta-

symptoms are not uncommon. The application may be

blockers (15). Magnesium deﬁciency has also been

limited in patients with elevated left ventricular end-

associated with vasospastic angina. Calcium-channel

diastolic pressure (LVEDP) because it is likely to

blockers and nitrates are the mainstays of therapy

worsen LVEDP. Riociguat potentiates the blood

for CAS. Occasionally, patients fail to achieve an

pressure–lowering effect of nitroglycerin, which is

adequate response despite combination therapy with

particularly problematic for patients with CAS because

alkaloids,

and

angina

by

includes

ergot

of

agent

nonselective

these drugs. In Japan, where CAS is more prevalent,

its use is contraindicated “with nitrates or nitric oxide

the incidence of intractable vasospastic angina ex-

donors in any form” (19). Riociguat utilizes the CYP3A

ceeds 13% (16). One strategy for dealing with re-

pathway. Therefore, ketoconazole and protease in-

fractory vasospastic angina is to use different

hibitors increase circulating levels of riociguat.

calcium-channel antagonists (dihydropyridine and

Conversely, nicotine exposure decreases circulating
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levels of riociguat. For smokers, dosage adjustments

ensure

may be necessary unless smoking cessation can be

therapy.

achieved. Bioavailability may be affected by antacids
containing

magnesium

or

aluminum

hydroxide,

its

clinical

recognition

and

appropriate
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which limit absorption. Particular caution is required

The authors have reported that they have no relationships relevant to

in women of child-bearing age. The drug is pregnancy

the contents of this paper to disclose.

category X and requires additional monitoring for all
women of reproductive potential.
In conclusion, coronary artery spasm remains alive
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